
Opinion|Videos|September 18, 2024
Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib
Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following:
How do these new therapy options (FTD/TPI plus bevacizumab, fruquintinib) compare with regorafenib in terms of efficacy and safety?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
OpenAI for Healthcare Aims to Streamline Clinical Workflows, Reduce Administrative Burden
2
Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data
3
Postpandemic Nursing Home Capacity Declines Tied to Longer Hospital Stays, Increased Patient Travel
4
Smarter Vaccination Strategies Could Strengthen Future Influenza Preparedness: Marco del Riccio, MD
5




























































